The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: Report from the children's oncology group

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 81-88

  Ho, Phoenix A ^a,b,c   Alonzo, Todd A ^c,d   Gerbing, Robert B ^c   Kuhn, Julia ^a,e   Pollard, Jessica A ^a,b,c   Hirsch, Betsy ^c,f   Raimondi, Susana C ^c,g   Gamis, Alan S ^c,h   Meshinchi, Soheil ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

AML; Molecular diagnosis and therapy; Prognostic factors; Rs16754; WT1

Indexed keywords

FLT3 LIGAND; MESSENGER RNA; WT1 PROTEIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOGENETICS; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; INFANT; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MORTALITY; NEWBORN; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, WILMS TUMOR; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84891722547     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24700     Document Type: Article

References (29)

1. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010;24: 35-63.
2. Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 2010;116: 702-710.
3. Ho PA, Kuhn J, Gerbing RB, et al. The WT1 synonymous SNP rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric AML: A report from the Children's Oncology Group. J Clin Oncol 2011;29:704-711.
4. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079.
5. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-1225.
6. Schmid D, Heinze G, Linnerth B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643.
7. Yanada M, Terkura S, Yokozawa T, et al. Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004;45:1803-1808.
8. Miglino M, Colombo N, Pica G, et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 2011;52: 1961-1969.
9. Noronha SA, Farrer JE, Alonzo TA, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009;53:1136-1139.
10. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Human Mol Genet 2006; 15:R196-R201.
11. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990;61:1257-1269.
12. Morrison AA, Viney RL, Ladomery MR. The post-transcriptional roles of WT1, a multifunctional zincfinger protein. Biochim Biophys Acta 2008;1785:55-62.
13. Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: The WT1 story. Leukemia 2007;21:868-876.
14. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hematopoiesis. Exp Hematol 1997;25:312-320.
15. Maurer U, Brieger J, Weidmann E, et al. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997;25: 945-950.
16. Miwa H, Beran M, Saunders GF. Expression of the wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
17. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2011;29:2889-2896.
18. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356-2364.
19. Ho PA,Kopecky KJ, Alonzo TA, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: A report from the Children's Oncology Group and SWOG. Blood 2011;118:4561-4566.
20. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 2012;118:761-769.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-1108.
22. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654-3661.
23. Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007;110:979-985.
24. Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the children's oncology group. Blood 2009; 113:6558-6566.
25. Loeb DM. WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. Cell Cycle 2006;5:1249-1253.
26. Siehl JM, Reinwald M, Heufelder K, et al. Expression ofWilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2005;83:745-750.
27. Kramarzova K, Stuchly J,Willasch A, et al. Real-time PCR quanitification of majorWilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia 2012;26:2086-2095.
28. Pollard JA, Alonzo TA, Gerbing RB, et al. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood 2006;108:2674-2679.
29. Pollard JA, Alonzo TA, Gerbing RB, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 2012;119:3705-3711.